Obermatt
See Similar Stocks →

Whitehawk Therapeutics

NAQ:WHWK · US00032Q1040
BiotechnologySmall

360

38
Medium confidence — indicative
Profit price28
Cash yield1
Price/Sales17
Price/Book36
Return on Capital35
Cash Return on Capital31
Return on Equity45
Profit margins5

Cash truth not applicable for financial companies.

Sales growth1
Profit growth63
Reinvestment82
Price momentum80
Debt load72
Refinancing35
Debt Payback1
Liquidity77
Analyst ratings9
Opinion Changes50
Price Target Upside23
Market mood9
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Whitehawk Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2007
Employees35
Websiteir.whitehawktx.com
ISINUS00032Q1040
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
OncologyBiopharmaBiotechnologyLife Science

Description

Whitehawk Therapeutics, Inc. is an oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. The company has deep experience in chemistry, formulati…

Analysis

Middle-of-the-road

Whitehawk Therapeutics, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
17
—
—
—
Price/Earnings
36
—
—
—
Price/Book
36
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
27
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Whitehawk Therapeutics with its peers
Prelude Therapeutics
NSQ:PRLD
49
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Day One Biopharmaceuticals
NSQ:DAWN
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Quince Therapeutics
NSQ:QNCX
4
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Crescent Biopharma
NAQ:CBIO
19
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immunome
NAQ:IMNM
40
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →